Publikationen, an denen er mitarbeitet Y. Quiros (7)

2024

  1. Urinary GM2AP coincides with renal cortical damage and grades cisplatin nephrotoxicity severity in rats

    Toxicology, Vol. 508

2021

  1. Urinary Plasminogen Activator Inhibitor-1: A Biomarker of Acute Tubular Injury

    American Journal of Nephrology, Vol. 52, Núm. 9, pp. 714-724

2020

  1. Combined use of GM2AP and TCP1-eta urinary levels predicts recovery from intrinsic acute kidney injury

    Scientific Reports, Vol. 10, Núm. 1

  2. Impaired Tubular Reabsorption Is the Main Mechanism Explaining Increases in Urinary NGAL Excretion Following Acute Kidney Injury in Rats

    Toxicological sciences : an official journal of the Society of Toxicology, Vol. 175, Núm. 1, pp. 75-86

2015

  1. Increased Klk9 urinary excretion is associated to hypertension-induced cardiovascular damage and renal alterations

    Medicine (United States), Vol. 94, Núm. 41

2011

  1. Urinary levels of regenerating islet-derived protein III Β and gelsolin differentiate gentamicin from cisplatin-induced acute kidney injury in rats

    Kidney International, Vol. 79, Núm. 5, pp. 518-528

2010

  1. Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein

    Kidney International, Vol. 78, Núm. 10, pp. 1006-1015